SCHEMBL21476669

SCHEMBL21476669

CCn1c(=O)cc(Cl)c2cc(C)ccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.47
HSD17B10 Q99714 2/20 0.47
POLB P06746 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PGR P06401 1/20 0.43
RORA P35398 1/20 0.43
RORC P51449 1/20 0.43
RORB Q92753 1/20 0.43
PTGDR2 Q9Y5Y4 4/20 0.42
KMT2A Q03164 3/20 0.42
LMNA P02545 2/20 0.42
MAPT P10636 5/20 0.40
ALDH1A1 P00352 4/20 0.40
MEN1 O00255 2/20 0.40
HTT P42858 1/20 0.40
PTGER4 P35408 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 4/20 0.40
AKR1B1 P15121 2/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5984776 0.83 KDM4E (0.64) KDM4EHSD17B10POLBL3MBTL1PGR
SCHEMBL20183820 0.83 KDM4E (0.45) KDM4EHSD17B10KMT2ALMNAMAPT
SCHEMBL20195076 0.80 PTGER4 (0.65) KDM4EHSD17B10POLBLMNAMAPT
SCHEMBL20183578 0.79 KDM4E (0.53) KDM4EHSD17B10POLBKMT2AMAPT
SCHEMBL829894 0.78 KDM4E (0.47) KDM4EHSD17B10POLBL3MBTL1KMT2A
SCHEMBL20183779 0.78 MAPT (0.60) KDM4EHSD17B10POLBKMT2ALMNA
SCHEMBL20183727 0.78 NPC1 (0.51) KDM4EHSD17B10POLBKMT2ALMNA
SCHEMBL20183699 0.78 KDM4E (0.43) KDM4EHSD17B10POLBL3MBTL1KMT2A
SCHEMBL1611235 0.77 KDM4E (0.52) KDM4EHSD17B10POLBL3MBTL1PGR
SCHEMBL21549489 0.76 KDM4E (0.43) KDM4EHSD17B10POLBL3MBTL1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10987349-B2 Antitumor agent and bromodomain inhibitor FUJIFILM CORPORATION (JP) 2021-04-27 US disclosed
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORPORATION (JP) 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10987349-B2 Antitumor agent and bromodomain inhibitor BRD4, BRD1, BRD3 KDM4E 1027/4885HSD17B10 3331/4885POLB 2400/4885
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR BRD4, BRD1, BRD3 KDM4E 1027/4885HSD17B10 3331/4885POLB 2400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.